Syntheses, Characterization, Crystal Structures and Xanthine Oxidase Inhibitory Activity of Hydrazones.

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Enzyme Inhibition

Background:

• Hydrazone derivatives are recognized for their diverse biological activities.
• Xanthine oxidase (XO) is a key enzyme in purine metabolism, implicated in conditions like gout.
• Fluorinated organic compounds often exhibit enhanced pharmacological properties.

Purpose of the Study:

• To synthesize novel fluoro-containing hydrazones.
• To evaluate the xanthine oxidase inhibitory potential of these synthesized compounds.
• To investigate the binding interactions of active compounds with the xanthine oxidase active site through molecular docking.

Main Methods:

• Synthesis of four new fluoro-containing hydrazones via condensation reactions.
• Characterization of synthesized compounds using IR and 1H NMR spectroscopy.
• X-ray single crystal diffraction for structural determination.
• In vitro evaluation of xanthine oxidase inhibitory activity.
• Molecular docking simulations using the crystal structure of xanthine oxidase.

Main Results:

• Successful synthesis and characterization of four fluoro-containing hydrazones: 3-chloro-N'-(4-fluorobenzylidene)benzohydrazide (1), 2-chloro-N'-(4-fluorobenzylidene)benzohydrazide (2), N'-(4-fluorobenzylidene)-4-nitrobenzohydrazide (3), and N'-(4-fluorobenzylidene)-3-nitrobenzohydrazide (4).
• Compounds 3 and 4, bearing nitro substituents, exhibited significant xanthine oxidase inhibitory activity.
• X-ray crystallography confirmed the structures of the synthesized hydrazones.
• Docking studies provided insights into the probable binding modes of the active compounds within the xanthine oxidase active site.

Conclusions:

• The synthesized fluoro-containing hydrazones represent a promising class of compounds for xanthine oxidase inhibition.
• Nitro-substituted derivatives show particular efficacy, suggesting their potential for therapeutic development.
• Molecular docking aids in understanding structure-activity relationships and guiding future drug design for XO inhibitors.